# Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

> **NCT05203003** · — · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 260 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** Assessment of MRD

## Key facts

- **NCT ID:** NCT05203003
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-22
- **Primary completion:** 2027-04
- **Final completion:** 2028-12
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203003, "Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05203003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*